The New York State Department of Health (NYSDOH), Bureau of Immunization has issued a Health Advisory on the use of nirsevimab (Beyfortus) to prevent lower respiratory tract infection caused by respiratory syncytial virus (RSV) in infants and young children.
The advisory provides guidance on the appropriate administration of nirsevimab for pediatric patients entering their first or second RSV season.
According to the Center for Disease Control and Prevention (CDC), RSV infection is the leading cause of hospitalization among U.S. infants with most children being infected during the first year of life, and nearly all children being infected by age 2 years.
The DOH advises providers to target administration just before the start of the RSV season, noting that “analyses suggest that RSV activity is returning to the typical seasonal pattern observed in pre-pandemic seasons when cases increased in the fall and peaked during the winter.”
Click the following link to view the full advisory: HEALTH ADVISORY: Respiratory Syncytial Virus Pediatric Immunization: Nirsevimab (Beyfortus)